Seo S, Xie H, Karron R A, Thumar B, Englund J A, Leisenring W M, Stevens-Ayers T, Boeckh M, Campbell A P
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Bone Marrow Transplant. 2014 Sep;49(9):1205-11. doi: 10.1038/bmt.2014.124. Epub 2014 Jun 30.
Parainfluenza virus type 3 (PIV-3) can cause severe respiratory illness among hematopoietic cell transplantation (HCT) recipients. Factors associated with PIV-3-specific Ab level, and the association between PIV-3 Ab levels and clinical outcomes in HCT recipients who acquire PIV-3 infection, are unknown. We evaluated PIV-3-specific hemagglutination inhibition Ab levels and clinical outcomes among 172 patients with PIV-3 infection following HCT. In a multivariable linear regression model, high post-transplantation Ab levels were independently associated with higher pre-transplantation recipient titer (mean difference 0.38 (95% confidence interval (CI), 0.26, 0.50), P<0.001). Significant associations between pre-HCT Ab titers in both patients and donors and occurrence of lower respiratory tract disease (LRD) after HCT were not observed. In conclusion, low pre-transplantation titers are associated with low Ab levels after HCT. The relationship between PIV-3 Ab levels and outcomes remain uncertain. Further study is needed to prospectively evaluate the dynamics of PIV-3-specific Ab responses and the relative contribution of PIV-3-specific Ab to protection from infection acquisition and progression to LRD.
3型副流感病毒（PIV-3）可在造血细胞移植（HCT）受者中引起严重的呼吸道疾病。与PIV-3特异性抗体水平相关的因素，以及在感染PIV-3的HCT受者中PIV-3抗体水平与临床结局之间的关联尚不清楚。我们评估了172例HCT后感染PIV-3的患者的PIV-3特异性血凝抑制抗体水平和临床结局。在多变量线性回归模型中，移植后高抗体水平与移植前受者较高滴度独立相关（平均差异0.38（95%置信区间（CI），0.26，0.50），P<0.001）。未观察到患者和供者移植前抗体滴度与HCT后下呼吸道疾病（LRD）发生之间的显著关联。总之，移植前滴度低与HCT后抗体水平低相关。PIV-3抗体水平与结局之间的关系仍不确定。需要进一步研究以前瞻性评估PIV-3特异性抗体反应的动态变化以及PIV-3特异性抗体对预防感染获得和进展为LRD的相对贡献。
